Programme

Thursday, January 31, 2019

Opening Talk

Time Presentation Title Speaker
08:30 – 09:00 Opening and Objectives W. Oyen,
G. Chételat

Thursday, January 31, 2019

PET as Part of the Biomarker Toolbox for Early Clinical Diagnosis of Alzheimer Disease (AD)

Chairpersons: J. Arbizu / V. Garibotto / P. Scheltens / S. Minoshima

Time Presentation Title Speaker
09:00 – 09:20 Unmet Need for Early Diagnosis of Prodromal AD B. Dubois
09:25 – 09:45 Contribution of MRI for Early Diagnosis of AD G. Frisoni
09:50 – 10:10 Contribution of CSF for Early Diagnosis of AD H. Zetterberg
10:15 – 10:35 Contribution of PET for Early Diagnosis of AD S. Minoshima
11:00 – 11:10 Controversy: Early Diagnosis of AD – PET in the Initial Work-Up J. Arbizu
11:10 – 11:35 Controversy: In Favour F. Nobili
11:40 – 12:05 Controversy: Against P. Scheltens
12:05 – 12:15 Questions & Answers all
12:15 – 13:00 Consensus on Imaging for Early Diagnosis of AD S. Minoshima,
J. Arbizu,
V. Garibotto

 

Thursday, January 31, 2019

Molecular Imaging in the Differential Diagnosis of Dementia

Chairpersons: S. Morbelli / J. Arbizu

Time Presentation Title Speaker
14:00 – 14:25 Contribution of MRI F. Agosta
14:30 – 14:55 Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration G. Rabinovici
15:00 – 15:25 Unmet Clinical Needs and Contribution of Molecular Imaging in Parkinsonian Syndromes D. J. Brooks
16:00 – 16:10 Controversy: FDG-First versus Amyloid-First for Differential Dementia Diagnosis? J. Arbizu
16:10 – 16:30 Controversy: FDG PET-First D. Perani
16:30 – 16:55 Controversy: Amyloid PET-First O. Sabri
16:55 – 17:10 Questions & Answers all
17:10 – 18:00 Consensus on Molecular Imaging for Differential Dementia Diagnosis J. Arbizu,
S. Morbelli

 

Friday, February 1, 2019

Clinical Acceptance of Amyloid Imaging

Chairpersons: V. Garibotto / A. Drzezga

Time Presentation Title Speaker
09:00 – 09:25 The Current Status of Amyloid Markers (PET and CSF) Reimbursement A. Nordberg
Round Table: Evidence for a Routine Use of Amyloid Markers
09:25 – 09:45 The Point of View of the Scientific Community S. Landau
09:50 – 10:10 The Point of View of the Payers and the Industry in the IMI-2 Initiative G. Frisoni
10:15 – 10:35 The Point of View of the Patients and the Families M. C. Carrillo
11:00 – 11:20 Ongoing Studies to Provide Answers: AMYPAD and Other European Initiatives F. Barkhof
11:25 – 11:45 Ongoing Studies to Provide Answers: IDEAS and Other Collaborative Efforts Worlwide G. Rabinovici
Discussion and Consensus
11:50 – 12:30 Consensus on Clinical Use of Amyloid Markers A. Drzezga
12:30 – 13:00 Consensus on Research Priorities V. Garibotto

 

Friday, February 1, 2019

The Use of PET in Dementia Research

Chairpersons: H. Barthel / G. Chételat / A. Drzezga

Time Presentation Title Speaker
14:00 – 14:20 Impact of Brain Connectivity and Reserve in Dementia G. Chételat
Round Table: The Complementarity of Neuroimaging Techniques in Clinical Trials i) to Enrich Target Populations and ii) to Monitor Drug Effects
14:25 – 14:45 FDG-PET Imaging K. Herholz
14:50 – 15:10 MR Imaging P. Scheltens
15:15 – 15:35 Amyloid and Tau-PET Imaging (TBC) V. Villemagne
16:00 – 16:10 Controversy: Guidelines for Research Criteria in Preclinical AD: Should Amyloid be Considered as the Lead Biomarker in the Hierarchy? A. Drzezga
16:15 – 16:35 Controversy: In Favour C. Jack
16:40 – 17:00 Controversy: Against A. Fjell
17:00 – 17:35 Consensus on Hierarchy of Biomarkers in Preclinical AD A. Drzezga
17:40 – 18:00 Do we Need Multimodal Imaging? A. Drzezga

 

Saturday, February 2, 2019

New Developments and Methodology

Chairpersons: I. Law / E. van de Giessen / H. Barthel

Time Presentation Title Speaker
09:00 – 09:20 Imaging of Neuroinflammation in Neurodegeneration – What does it Add to Our Understanding? D.J. Brooks
09:25 – 09:45 Principles of Absolute PET Quantification for Monitoring Longitudinal Treatment Response? A. Lammertsma
09:50 – 10:10 Amyloid and Tau Imaging: Centiloid, Centaur, and Clinical Use V. Villemagne
10:15 – 10:35 PET-Tau Imaging for Early and Differential Diagnosis of AD O. Hansson
11:00 – 11:20 Standards for In-Vitro Validation of PET Tracers in Neurodegeneration A. Nordberg
11:25 – 11:55 Hybrid PET/MRI: Has it Developed the Dementia Field?
H. Barthel
12:00 – 12:20 Issues in Quantification for Neurological PET Studies B. Hutton
12:25 – 13:00 Discussion: What else do We Need for Progress? (New Tracers, Artificial Intelligence, etc.)
I. Law,
E. van de Giessen